| ABBV |
Report |
Skyrizi Revenue (Q2 2026) |
BEAT |
pred ~$5.60B vs. cons $5.44B |
HIGH |
| ABBV |
Report |
Neuroscience Revenue (Q2 2026) |
BEAT |
pred ~$3.20B vs. cons $3.12B |
HIGH |
| ABBV |
Report |
Adj. EPS ex-IPR&D (Q2 2026) |
BEAT |
pred ~$3.68 vs. cons $3.61 |
MEDIUM |
| ABBV |
Guide |
Total Revenue (FY 2026) |
BETTER |
guide ~$67.7B vs. cons $67.4B |
HIGH |
| ABBV |
Guide |
Adj. EPS ex-IPR&D (FY 2026) |
BETTER |
guide ~$14.45 midpoint vs. cons $14.09 |
MEDIUM |
| ABBV |
Guide |
Q3 2026 Revenue |
BETTER |
guide ~$17.0B vs. cons $16.8B |
MEDIUM |
| ABBV |
Guide |
Aesthetics tone (FY 2026) |
UNCHANGED |
maintained ~$5.0B, cautious tone vs. cons $4.98B |
HIGH |
| ABBV |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| ABBV |
Return |
5-day cumulative residual |
+3.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — FY raise forces H2 estimate revisions upward; implied H2 ~$2B above current consensus pulls sell-side models higher over 3-5 days |
MEDIUM |